

RESCON USA
SUMMIT 2024

Inhalation & RESpiratory Drug
Delivery | CONnected Devices



14 – 15 November 2024

Hyatt Centric Times Square New York



DIAMOND SPONSORS



GOLD SPONSORS



SILVER SPONSORS



EXHIBITORS & PARTNERS



MEDIA PARTNERS



World With Science
www.kindcongress.com

Welcome to **RESCON Summit**, the premier event dedicated to Inhalation & Respiratory Drug Delivery. Join us for two days of in-depth discussions and networking opportunities with leaders in the pharmaceutical and biotech industries. Explore the latest advancements in inhalation drug delivery, from formulations to devices, and gain insights into the future of respiratory therapies. At RESCON Summit, the spotlight is on business-to-business interactions, fostering collaborations that will drive innovation in patient care. Don't miss this exclusive opportunity to connect with industry experts and shape the future of respiratory health.

EPM Group Executive Summary

WHO You Will Meet



80+
Attendees



25+
Speakers


RATIO

Bio/pharmaceutical
manufacturing

65:35


Vendor/Solution
Providers

Company Size of Attendees




- 1000+ employees
- 300-999 employees
- 50-299 employees
- less than 49 employees

Job Title of Attendees



- C-level
- SVP/VP
- Snr Director/Director
- Snr Manager/Manager

Attendee Company Annual Turnover



- 1 Billion
- \$500-999 Million
- \$50-499 Million
- <50 Million

HOW You Will Benefit



x1000+

Relive the conference. Full access to documentation, footages and videos.



x10+

'Hours of Networking. Forge new professional contacts.



x20+

Case Studies Analysis

Companies Attending Our Events



FEEDBACK

94%

RATED EVENT



Quality of the speakers
Sharing of the best practices
Spectrum of industries
Intimate atmosphere

98%

WOULD RECOMMEND
THE EVENT TO
COLLEAGUES



Learn

The Key Practical Points

Regulatory Strategies:

Learn how to develop and execute effective regulatory strategies for connected devices and digital health products in respiratory care.

Chronic Diseases:

Understand the latest advancements in inhaled biotherapeutics for treating chronic lung diseases like asthma and COPD.

R&D in Lung Cancer:

Explore the journey from preclinical research to patient treatment for inhaled lung cancer therapies.

Technological Innovations:

Discover new technologies for producing respirable particles for inhalation therapies.

Low-GWP Propellants:

Gain insights into the transition to sustainable propellants in pMDIs and their regulatory implications.

Device Design:

Learn about the challenges and strategies in designing dry powder inhalers to enhance pulmonary drug deposition.

Regulatory Compliance:

Understand the critical regulatory requirements and compliance strategies for inhalation drug products.

Combination Therapies:

Explore current products and future developments in drug combinations for inhalation to improve disease control and patient compliance.

Environmental Impact:


Learn about the environmental considerations in respiratory drug delivery and how to future-proof pMDIs.

Connected Devices:

Discover the role of connected devices in monitoring inhaler use and improving patient adherence in real-world settings.

Technology and know-how

YOUR INHALATION PRODUCT IN FOCUS



We have many years of expertise in development and production equipment for drug delivery in inhalation and nasal applications. Our experts can support you in all aspects of the development and optimization of your inhalation product.

- Expertise in microdosing, sealing and assembly
- Turnkey solutions for inhaler industrialisation
- From clinical trials to commercial production
- Integration of dose verification and PAT

Looking forward to your visit at Rescon Summit, New York 2024

Meet The Speakers



**Joshua
Ziel**

Chief Executive Officer
at Bryn Pharma



**Teresa
Carvajal**

Faculty Member, Prof
Agricultural and Biological
Engineering, Purdue
University.



**Stephen F.
Flaim**

Senior Special Advisor &
Investor-In-Residence at
National Heart Lung and
Blood Institute, NIH



**Jyothi
Menon**

Associate Professor at
University of Rhode Island



**Rémi
Rosière**

Chief Scientific Officer at
InhaTarget Therapeutics



**C. Vivek
Lal**

Founder & Executive
Chairman at Alveolus Bio




**Bryan
Bobo**

Principal Consultant at
Suttons Creek, Inc.




**Craig
Voellmicke**

Director of Sales at
Suttons Creek, Inc.



Francesca Buttini

Associate Professor at the Food and Drug Department, University of Parma (IT)



Marian Asch

Sales Director Inhalation Technologies at Harro Höfliger



Bernhard Müllinger

General Manager, COO at Resyca



Yu Feng

Associate Professor at Oklahoma State University



David Jürgens

Chief Operating Officer (COO) at RNhale GmbH



Peter Small

Chief Medical Officer at Hyfe Inc.



David Edwards

Founder Sensory Cloud, Adjunct Professor Johns Hopkins Medical School, Associate School Engineering Harvard University



Blake McEvoy

Head of US Corporate Affairs, Respiratory & Immunology, Vaccines & Immune Therapies at AstraZeneca



Priyal Patel

Associate Scientist in the Drug Delivery & Formulation at Sanofi



Zaid Nabulsi

Machine Learning Software Engineer at Google



Kalpita Nadkar

Senior Manufacturing Associate at Bristol Myers Squibb



Robert Hartwig

Business Development Manager at Mematec Solutions



Cory Costantino

Design Director Human Factors Research & Design at Emergo by UL



Carla Vozone

VP Inhalation Strategy, Innovation and Partnerships at Catalent Pharma Solutions



Ryan Elmore

Biomaterials Business Director at Victrex plc



Mark Ignaczak

Director, Innovation and Partnerships – Nasal Delivery, Catalent



Cecilia Gonzalo

Partner at Oberland Capital



Scott Ariagno

Vice-President of Engineering and Development Services at EdgeOne Medical



Eric Uffman

Director of Sales – North America at Proveris Laboratories

YOUR PARTNER...

FROM DEVELOPMENT TO APPROVAL



DEVELOPMENT



CMC SERVICES



COMMERCIAL TESTING

Scientific expertise and testing strategies for innovator and generic OINDPs

- Human Usage Studies
- Nasal Cast Studies
- Device and Formulation Screening
- Method Development
- **Alternative BE Studies**
 - Plume Front Velocity
 - Regional Drug Deposition
 - Evaporation Fraction
- *In Vitro* Testing
- Drug Product Characterization
- Priming/Repriming
- Device Robustness
- Device Reliability Studies
- Development Stability Studies
- Root Cause Analysis
- OOS/OOT Investigations
- Product Consultation when Design, Supply Chain or Manufacturing Changes Occur
- Method Validation and Transfer



LEARN MORE:

www.proveris.com/proveris-laboratories/
contactus@proveris.com
+1 508 460-8822



Scientific Agenda

DAY 0 WEDNESDAY, NOVEMBER 13TH

6:00PM - 8:00PM | Pre-Conference
Cocktail Reception

Location:
Hyatt Centric Bar 54 | Rooftop
Bar (54th Floor)
135 W 45th St, New York, NY
10036, USA

DAY 1 THURSDAY, NOVEMBER 14TH

8:30AM | Conference Registration

Morning Sessions Chairperson:
Teresa Carvajal, Purdue University.

8:55AM | RESCON Summit
Opening Speech

Session 1:
Innovations in Inhalation Therapies

9:00AM | **Inhaled biotherapeutics for chronic lung diseases**
C. Vivek Lal, Founder & Executive Chairman at Alveolus Bio

9:30AM | **Inhaled alkaline HDS for treatment of refractory chronic cough**
David Edwards, Founder Sensory Cloud, Adjunct Professor Johns Hopkins Medical School, Associate School Engineering Harvard University

10:00AM | **Speed Networking**

10:30AM | **Morning Coffee Break**

11:00AM | **Probiotics and Proteins Love the Lungs**
Francesca Buttini
Associate Professor at the Food and Drug Department, University of Parma (IT)

11:30AM | **Dry Powders in Nasal Drug Delivery: Current and Emerging Products and Production Processes**
Marian Asch
Sales Director Inhalation Technologies at Harro Höfliger

12:00PM | **Emerging Trends in Nasal Drug Development and Delivery**
Mark Ignaczak, Director, Innovation and Partnerships – Nasal Delivery, Catalent

12:30PM

Next-Generation Nasal Sprays: Potential for Intranasal Delivery of CNS Therapies and mRNA Vaccines

Bernhard Müllinger, General Manager, COO at Resyca

1:00PM

Lunch Break

Afternoon Sessions Chairperson:

Francesca Buttini, University of Parma

Session 2:

Cutting-edge Research and Development

2:00PM

Overcoming Product Development Challenges for OINDPs: Accelerating Progress with Advanced Analytical Tools

Eric Uffman, Director of Sales – North America at Proveris Laboratories

2:30PM

"Inhalable Dry Powder LNPs For Severe Asthma Therapy - From Bench to Bedside"

David Jürgens, Chief Operating Officer at RNhale GmbH

3:00PM

Delivering therapies to the lungs to activate the immune system against lung tumors

Rémi Rosière, Chief Scientific Officer at InhaTarget Therapeutics

3:30PM

Going Green: Key considerations for pMDI

Kalpita Nadkar, Senior Manufacturing Associate at Bristol Myers Squibb

4:00PM

Afternoon Coffee Break

4:30PM

Panel Discussion: Evolving Regulatory, Policy, and Investment Approaches in Respiratory Health

- Navigating key regulatory challenges and compliance strategies in the evolving healthcare landscape.

- Impact of national and state policy changes on COPD diagnosis, management, and overall healthcare costs.

- Integrating a OneLung approach to public health issues: Addressing lung cancer, COPD, and asthma through equitable, sustainable practices.

- Future innovations in regulatory frameworks and market dynamics for respiratory health.

- Investment strategies and funding innovations for advancing respiratory health technologies and delivery systems

Panelists:

- Blake McEvoy, AstraZeneca
- Bernhard Müllinger, Resyca
- Cecilia Gonzalo, Oberland Capital
- Joshua Ziel, Chief Executive Officer at Bryn Pharma
- Stephen F. Flaim, National Heart Lung and Blood Institute, NIH

Moderated by:

Carla Vozone, Catalent Pharma Solutions

8:00PM - 10:00PM | **Executive Networking Dinner**
Hyatt Centric Bar 54 |
Rooftop Bar (54th Floor)
135 W 45th St, New York, NY
10036, USA

DAY 2 FRIDAY, NOVEMBER 15TH

8:00AM | **Registration of RESCON Summit 2nd Day**

Morning Sessions Chairperson:
Bernhard Müllinger, Resyca

Session 3:
Formulation and Device Development

8:30AM | **Empowering medical devices to perform better and deliver improved patient outcomes**
Ryan Elmore, Biomaterials Business Director at Victrex plc

9:00AM | **mRNA-LNP Dry Powder for pulmonary deliver**
Priyal Patel, Associate Scientist in the Drug Delivery & Formulation at Sanofi

9:30AM | **Inhalable Nanotherapeutics to Overcome Physiological Barriers in Pulmonary Drug Delivery**
Jyothi Menon, Associate Professor at University of Rhode Island

10:00AM | **Reflecting on EdgeOne Medical's Decade of Inhaler Testing and Development**
Scott Ariagno
Vice-President of Engineering and Development Services at EdgeOne Medical

10:30AM | **Morning Coffee Break**

11:00AM | **Simplifying the complexities of combination product development: Lessons learned across the industry**
Craig Voellmicke
Director of Sales at Suttons Creek, Inc.
Bryan Bobo
Principal Consultant at Suttons Creek, Inc.

11:30AM | **"Define the unmet needs and review potential solutions to produce respirable particles: A technological perspective"**
Teresa Carvajal, Faculty Member, Prof Agricultural and Biological Engineering, Purdue University.

Session 4:
Innovative Inhalation Solutions and User-Centric Design

12:00PM | **Tomorrow's Platform for MDPI's-The Next Generation of MDPI Devices offering Variable Dosing and Variable Density Capabilities**
Robert Hartwig, Business Development Manager at Mematec Solutions

12:30PM

What are you telling me to do? - The human factors of connected features, data overload, and AI in medical device interfaces

Cory Costantino, Design Director Human Factors Research & Design at Emergo by UL

2:30PM

Artificial Intelligence (AI) Empowered User-Centered Smart Inhaler for Achieving Personalized Targeted Drug Delivery

Yu Feng, Associate Professor at Oklahoma State University

1:00PM

Lunch Break

**Afternoon Sessions Chairperson:
David Edwards, Sensory Cloud**

3:00PM

Cough Science: Novel Insights From AI Enabled Monitoring

Peter M. Small, M.D. Chief Medical Officer Hyfe, Inc

**Session 5:
Connectivity & Next-Generation Inhalation Devices**

3:30PM

Closing remarks & end of RESCON Summit 2024

2:00PM

Developing AI Tools for Computer Aided Diagnostics of Pulmonary Conditions

Zaid Nabulsi, Machine Learning Software Engineer at Google



ARE YOU READY FOR INHALATION DEVICE DEVELOPMENT?

The trusted partner to top 20 global biopharmaceutical companies



125+

Clients Served



60+

Submissions



50+

Development Programs




Biographies



Joshua Ziel Chief Executive Officer at Bryn Pharma

A scientist by training, Dr Ziel has spent his career working within and around Pharma and Biotech on some of the most consequential products and product candidates in hematology-oncology, rare disease, and respiratory. He brings a unique blend of strategic insight and operational expertise gleaned from working across the

product development lifecycle, from early clinical development to commercialization. Currently the CEO of Bryn Pharma, Dr. Ziel leads Bryn's team of development and commercialization experts towards completion of the regulatory pathway for NDS1C, a potentially best-in-class intranasal epinephrine treatment for anaphylaxis.



Teresa Carvajal Faculty Member, Professor at the Department of Agricultural and Biological Engineering at Purdue University

Teresa Carvajal holds a faculty appointment at Purdue University in the Agricultural and Biological Engineering department, College of Agriculture and Engineering. Prior to joining Purdue University, she worked in the pharmaceutical industry for 13 years, solid, liquid and dry powder inhaler formulation development at Hoffmann-LaRoche (NJ); at Transave (NJ) formulation and characterization of inhalation aerosols; and pre-

formulation activities at Bayer (CT). She has a Ph.D. in Powder Technology from the University of Bath, UK, M.S. in Physical Pharmaceutics, a minor in Physical Chemistry from the University of Arizona, USA and B.S. in Chemical Pharmaceutical Biologist from the UNAM, México. Teresa's main research interests focus on powdered biomaterials relevant to pharmaceutical, food and environmental.



Stephen F. Flaim Senior Special Advisor & Investor-In-Residence at National Heart Lung and Blood Institute, NIH

Dr. Flaim holds a doctorate in Human Physiology and Pharmacology from the University of California at Davis. He held faculty positions in Medicine & Physiology at the Pennsylvania State University College of Medicine and senior management roles at the Johnson & Johnson Pharmaceutical Research Institute, the Squibb Institute for Medical

Research, Alliance Pharmaceutical Corporation, Trega Biosciences, Inc., Galileo Pharmaceuticals, Inc., OncoFluor, Inc., CardioCreate, Inc. and Leading Biosciences, Inc. Dr. Flaim is a Fellow of the American College of Cardiology, the American Heart Association, the American College of Clinical Pharmacology & the Royal Society of Medicine.



Jyothi Menon Associate Professor at University of Rhode Island

Dr. Jyothi Menon is an Associate Professor of Biomedical and Pharmaceutical Sciences, and Chemical Engineering at the University of Rhode Island. She received her Master's and PhD degrees in Biomedical Engineering from the joint program between the University of Texas (UT) Southwestern Medical Center, Dallas and UT Arlington in 2010 and 2014 respectively. She then joined the University

of Oxford, UK where she worked as part of a multidisciplinary team to develop nanoparticles for targeted radiotherapy. She joined the University of Rhode Island in 2017, and her current research focus is on developing inhalable nanoparticle-based targeted drug delivery formulations to treat pulmonary disorders including lung cancer, pulmonary fibrosis and COPD.



Rémi Rosière Chief Scientific Officer at InhaTarget Therapeutics

Rémi Rosière hold a master's degree in pharmaceutical and biomedical sciences (Université libre de Bruxelles (ULB) 2010) and obtained a PhD degree (ULB, 2016) for research completed at the Unit of Pharmaceutics and Biopharmaceutics, where he still has a position of

lecturer. He has been the lead researcher in charge of the Inhatarget spin-off project since 2015. This project led to the launch of the pharma start-up InhaTarget Therapeutics that he co-founded in 2019.



C. Vivek Lal Founder & Executive Chairman at Alveolus Bio

Dr. C. Vivek Lal, M.D. is a physician scientist, innovator and entrepreneur. He is the Clinical Director of Innovation at The Marnix Heersink Institute of Biomedical Innovation, Professor and the Director of Pulmonary Microbiome Lab at University of Alabama at Birmingham (UAB). Dr. Lal is the Founder and CEO of ResBiotic Nutrition, Inc.,

a company that makes science backed wellness supplements. He is also the founder of Alveolus Bio, Inc., a platform biotech company which does FDA approved pulmonary drug development & Urgent Care for Children, a Southeast US based urgent care chain headquartered in AL.



Bryan Bobo Principal Consultant at Suttons Creek, Inc.

With over 9 years of experience in the pharmaceutical industry, Bryan has extensive knowledge of combination product development and what it takes to launch products on the market. He has practical and hands-on experience in various types of drug delivery systems from his years as both a Device Development Engineer

as well as project and program management positions. In addition to his direct product development experience, Bryan engages with the global combination product community through his participation on various international standards committees as well as other various industry forums.



Craig Voellmicke Director of Sales at Suttons Creek, Inc

With more than 19 years of medical device and Combination Product experience and an MBA from NYU's Leonard N. Stern School of Business, Craig applies both hands-on technical experience and a strong business development acumen on the job and as a guest lecturer at NYU's Biomedical Entrepreneurship Program, speaking on commercialization and business development. Craig began his career as an engineer, designing and developing drug delivery devices at Becton

Dickinson, where he gained 11 years of exposure to clinical practice and the commercialization of medical devices. After earning his MBA, his focus shifted to business development strategies and execution for prefilled syringes and medical devices, when he quickly became Terumo Medical's top performer on their US B2B Pharma team and played key roles for the company's Japan and EU headquarters, launching and growing ocular and intramuscular drug delivery portfolios.



Francesca Buttini Associate Professor at the Food and Drug Department, University of Parma (IT)

Francesca Buttini is currently holding an Associate Professor position at the Food and Drug Department, University of Parma (IT) and where now she is leading the unit dedicated to design of pharmaceutical products for inhalation. In 2014, she was appointed as Visiting Lecturer at the Institute of Pharmaceutical Science of King's College London (UK). Combining her background in pharmaceutical technology, regulatory aspects,

and device design, she is executing research programs aimed to deliver medicinal products that take into consideration the patient, industrial and regulatory requirements. Up to date, she has published more than 80 original papers and as a result of her research achievement she obtained in 2017 the DDL Emerging Scientist Awards from the UK Aerosol Society.



Marian Asch Sales Director Inhalation Technologies at Harro Höfliger

Marian Asch has a BSc. degree in business and engineering from University of Stuttgart. He started his career as Project Manager in Harro Hoefligers Business Unit Inhalation in 2017. In this role he managed DPI projects of multinational

pharma clients worldwide. Since summer 2021, Marian Asch works as a Sales Director for Inhalation Technologies focusing on business development and sales for dry powder inhaler pharma industry.



Bernhard Müllinger General Manager, COO at Resyca

Bernhard is the General Manager and Chief Operations Officer of Resyca and is based in Munich. Bernhard has experience with smart nebuliser devices and has worked in this industry for most of his career. He has extensive knowledge in medical

device development and clinical development of combination products. Prior to joining Resyca, Bernhard worked at Vectura, Activaero, Inamed-CRO, Asklepios Clinic and Helmholtz-Zentrum.



Yu Feng Associate Professor at Oklahoma State University

Dr. Yu Feng is an Associate Professor in the School of Chemical Engineering at Oklahoma State University (OSU). He is also a center investigator in the Oklahoma Center for Respiratory and Infectious Diseases (OCRID). Dr. Feng completed his B.S. in Engineering Mechanics at the School of

Aeronautics and Astronautics, Zhejiang University, China, in 2007. He pursued further education at the Department of Mechanical and Aerospace Engineering at North Carolina State University, where he obtained his M.S. and Ph.D. degrees in 2010 and 2013, respectively.



David Jürgens Chief Operating Officer (COO) at RNhale GmbH

David is a passionate scientist, COO, and co-founder of RNhale, focused on innovating practices in inhalation-based medicine. He began his career with preclinical work on inhalable mRNA therapeutics before pursuing a PhD at the Chair of Drug Delivery at LMU Munich. At LMU, he co-

founded RNhale, aiming to develop the next generation of inhalable drugs. David is working on pioneering RNA-based treatments for severe asthma using advanced Nano-Embedded in Microparticle (NEM) technology.



Peter Small Chief Medical Officer at Hyfe Inc.

Dr. Peter Small is the Chief Medical Officer of Hyfe, a company pioneering the use of acoustic AI to improve human health. Dr. Small has spent his career focusing on developing and delivering innovative solutions to improve health globally. His long standing interest in tuberculosis began while Chief Medical Resident under Dr. Phil Hopewell

at UCSF during the dawn of the HIV epidemic. He completed an Infectious Disease fellowship and spent about a decade on the faculty at Stanford Medical School. During these years, he published molecular epidemiological papers that helped to shape the public health response to the resurgence of tuberculosis.



David Edwards Founder Sensory Cloud, Adjunct Professor Johns Hopkins Medical School, Associate School Engineering Harvard University

David Edwards is a scientist, inventor and writer. The founder and inventor of FEND, 2020 Time Magazine Best Invention of the Year, a new daily rite for cleansing the lungs, David's inventions and startups have led to FDA-approved products on the market such as Inbrijia (inhaled L Dopa for Parkinson's). David was Professor of the Practice of Bioengineering at Harvard University in the School of Engineering & Applied Sciences from 2001 to

2019, and transitioned to Associate at the start of the pandemic to help pioneer the science and global clinical trial program of airway hydration. At Harvard, David's innovation learning programs have helped pioneer new ways of thinking about the translation of high-impact ideas as captured in his most recent book *Creating Things That Matter* (Holt 2018), Nautilus Book Award winner in 2018 in the category of creativity.



Blake McEvoy Head of US Corporate Affairs, Respiratory & Immunology, Vaccines & Immune Therapies at AstraZeneca

As AstraZeneca's Head of US Corporate Affairs for Respiratory & Immunology (R&I), Vaccines & Immune Therapies (V&I) Blake McEvoy is responsible for driving the development and execution of integrated external and internal Corporate Affairs strategies, working closely with senior leadership of the US and Global

therapy area teams and departments within US Corporate Affairs spanning External Affairs, Internal Communications, Advocacy and Alliance, Policy and Government Affairs to deliver fully integrated communications plans that help achieve the therapy area's vision, goals and objectives.



Priyal Patel Associate Scientist in the Drug Delivery & Formulation at Sanofi

Priyal Patel has a solid foundation in scientific research, which she leverages to lead transformative projects from conception through execution, ensuring the delivery of high-impact solutions in the fast-paced pharmaceutical landscape. She holds a Master of Science in Pharmaceutical Sciences from Northeastern University and a Bachelor of Pharmacy from Rajiv Gandhi


University of Health Sciences, India. After finishing her bachelor's in 2016, she came to Northeastern University, Boston, USA, to pursue her passion in the field of advanced drug delivery systems. Her career has afforded her the opportunity to work with prestigious organizations such as Sanofi, Translate Bio, and Moderna Therapeutics.



Zaid Nabulsi Machine Learning Software Engineer at Google

Zaid Nabulsi obtained his B.S. and M.S. from Stanford University, both in computer science and specialized in Artificial Intelligence. Zaid is currently a researcher at Google Research where he is on the Health AI team. Zaid's main research interests are computer aided diagnostics for

radiology (specifically Lung CT and ChestX-Ray modalities) and health audio models. Zaid has over 10 peer-reviewed publications at various journals and conferences.



Kalpita Nadkar Senior Manufacturing Associate at Bristol Myers Squibb

Kalpita Nadkar is a seasoned pharmaceutical drug product and process development professional, specializing in niche dosage forms like Pressurized Metered Dose Inhalers (pMDIs), Lyophilized drug products and CAR-T cell therapy operations. With a Master of Science in Pharmaceutical Sciences

from Campbell University, USA her expertise spans innovator (GSK, BMS) and generic industries (Aurobindo Pharma and Odin Pharmaceuticals), CRO/CDMO labs, across diverse drug development portfolios.



Robert Hartwig Business Development Manager at Mematec Solutions

Mr. Hartwig is Managing Director of BTS International LLC, a consulting group of highly skilled individuals providing consulting services for all aspects of the packaging machine industry, with particular emphasis on the pharmaceutical market. He is currently working with Mematec Solutions as Business Development Manager. With


50 years of experience in the packaging equipment and package development area of the Pharma industry, he has installed nearly 300 packaging lines (including blister filling for MDPI's and various inhalation device lines) and has worked with US, European, and Asian firms on packaging line development.



Cory Costantino Design Director Human Factors Research & Design at Emergo by UL

For 25 years, Cory has helped guide products, from hand-held consumer electronics to medical devices and software user interfaces, from concept to production. Cory is a board-certified human factors professional. He received his M.S. in Human Factors in Information Design from Bentley University and his B.S. in Industrial Design from Wentworth Institute of Technology. Cory oversees

and contributes to a wide range of projects, including software user interfaces, instructional materials, hardware/ergonomic design reviews, and multi-phase projects, where he often contributes to user research and usability testing. Cory has served as design director and co-founder of two start-up companies, an adjunct professor of design, and as a design consultant.



Carla Vozone VP Inhalation Strategy, Innovation and Partnerships at Catalent Pharma Solutions

Carla Vozone is Vice President of Inhalation Strategy, Innovation and Partnerships at Catalent Pharma Solutions. Carla leads strategic growth initiatives for Catalent's Inhalation business segment and oversees Product Development for Nasals and Inhaled Powders. She holds a PharmD and MSc in Pharmaceutical Technology from the Pharmacy School, University of Lisbon, a Master in Business

Administration (MBA) with a specialization in Pharmaceutical Management from Rutgers Business School, New Jersey and a Certification in Business Development and Licensing from the University of Manchester. Carla is Immediate Past Chair of IPAC-RS, the leading industry consortium on regulatory science of orally inhaled and nasal drugs (OINDPs).



Ryan Elmore Biomaterials Business Director at Victrex plc

Ryan works with Pharmaceutical, Biotech and Medical Device companies to help them increase their design and performance boundaries through using high performance materials. The VICTREX PCT™ PEEK polymers are a range of Pharmaceutical

Contact materials that enable designers and engineers to innovate and meet the ever increasing demands placed on parts. Ryan has been helping medical companies solve problems through Victrex materials since 2010.



Mark Ignaczak Director of Innovation and Partnerships at Catalent Pharma Solutions

Mark Ignaczak is Director of Innovation and Partnerships – Nasal Delivery at Catalent, Mark leads strategic growth initiatives and partnerships for Catalent's Nasal Liquid and Powder business, with an extensive background in nasal spray product development and commercialization. He holds a BS in Biochemical Engineering from

Rutgers–New Brunswick (NJ, US). Mark has 21 years of pharmaceutical experience and over 17 years of direct experience with nasal spray products. In that time, he has worked on 75+ nasal programs in varying stages within the project lifecycle, ultimately launching 10+ NDAs – some considered first-of-their-kind, best-in-class therapies.



Cecilia Gonzalo Partner at Oberland Capital

Ms. Gonzalo is a Partner at Oberland Capital. Prior to joining Oberland, she was a Managing Director at Vatera Healthcare Partners where she focused on venture capital and private equity investments in the biopharmaceutical industry. Previously, Ms. Gonzalo was a Managing Director with Essex Woodlands, a healthcare-focused growth equity firm, and with the healthcare group of Warburg Pincus, a global private equity firm. Ms. Gonzalo began her career at Goldman Sachs as an Analyst

in the firm's Investment Banking Division and Principal Investment Area. Ms. Gonzalo is an honorary member of the Planning Committee and Founding Co-Chair of the Respiratory Innovation Summit, which is hosted by the American Thoracic Society and seeks to unite leading companies, innovators, investors, clinicians and advocacy groups to accelerate innovation in the respiratory space and bring new treatments to patients.



Scott Ariagno Vice-President of Engineering and Development Services at EdgeOne Medical

Scott Ariagno is Vice-President of Engineering and Development Services at EdgeOne Medical and has over 25 years' experience in medical device and combination product design, development and manufacturing. His expertise includes development and global launch of various single-use, disposable medical devices, infusion systems and combination products, strategic/technical development of device platforms and IP development. Throughout his career,

he has held management roles in engineering including heading device development at Baxalta (a subsidiary of Shire, now Takeda). Mr Ariagno is a named inventor on over 20 patents and applications. He has Bachelor of Science in Mechanical Engineering from Bradley University (Peoria, IL, US) and a Master in Engineering Management from Northwestern University (IL, US).



Eric Uffman Director of Sales – North America at Proveris Laboratories



Eric is a seasoned expert in providing analytical services and solutions with over 19 years of experience in the pharmaceuticals and life sciences industries. Eric holds a Ph.D. in Organic Chemistry and has a diverse background that includes roles as scientist, laboratory manager, and commercial leader. Notably, Eric has served as Director of

Sales for medical device testing services, where he significantly contributed to business growth and success. Eric's passion for the life sciences drives his commitment to connecting clients with innovative solutions to advance their product research and development for patients to have access to life-changing and lifesaving medications.



Hyatt Centric Times Square New York Hotel

The RESCON Summit 2024 will be hosted at the Hyatt Centric Times Square New York, located in the heart of Manhattan. This vibrant hotel offers modern guest rooms and suites with stylish décor, upscale amenities, and floor-to-ceiling windows that provide breathtaking views of the city skyline. With its prime location, the Hyatt Centric is a perfect gateway to New York's most iconic attractions, from Central Park and Broadway theaters to world-renowned dining and shopping destinations. Attendees can enjoy unique gathering spaces and conclude their evenings at Bar 54, the hotel's rooftop bar perched above the city. Join us for an unforgettable experience at this contemporary boutique hotel, where New York City's energy and charm are at your doorstep.



135 W 45th St, New York, NY
10036, USA

